Dec 16 (Reuters) - Contineum Therapeutics Inc CTNM.O:
CONTINEUM THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1B POSITRON EMISSION TOMOGRAPHY $(PET.AU)$ TRIAL OF PIPE-791
CONTINEUM THERAPEUTICS INC - TOPLINE DATA READOUT EXPECTED IN Q2 2025
CONTINEUM THERAPEUTICS INC - DOSES FIRST COHORT IN PIPE-791 PHASE 1B TRIAL
CONTINEUM THERAPEUTICS INC - ANTICIPATES TOPLINE DATA FROM PIPE-791 TRIAL IN Q2 2025
Source text: ID:nBwbSfwCza
Further company coverage: CTNM.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.